The FDA pathway you choose determines your timeline, your evidence burden, and the long-term regulatory standing of your device. The 510(k) and De Novo processes exist for different situations. Choosing the wrong one leads to wasted preparation costs, an unexpected Not Substantially Equivalent (NSE) determination, or a delayed market entry.
In this article:
- Why predicate availability is the one question that determines which pathway you qualify for
- How the De Novo process works, including two submission routes most manufacturers overlook
- Where 510(k) and De Novo actually diverge on cost and timeline
- How to select the right pathway, plus one pre-submission tool that prevents costly misclassifications
The 510(k) Pathway: Substantial Equivalence
The 510(k) premarket notification requires demonstrating substantial equivalence to a legally marketed predicate device. The FDA evaluates two criteria:
- Your device must share the same intended use as the predicate.
- Its technological characteristics must be the same, or, if different, must not raise new questions about its performance.
When the FDA confirms substantial equivalence, it issues a Substantially Equivalent (SE) letter. That letter is clearance. The device can go to market.
510(k) Pathway at a Glance
| Factor | Details |
|---|---|
| Eligible Devices | Class I and Class II devices with a legally marketed predicate |
| Standard to Demonstrate | Substantial equivalence |
| FDA Outcome | Substantially Equivalent (SE) letter |
| FDA Review Goal (MDUFA V) | 90 days (95% of submissions) |
| FY2026 Standard User Fee | $26,067 |
| FY2026 Small Business Fee | $6,517 |
| Clinical Data | Not routinely required |
| Preparation Time | 3–6 months |
Bench testing satisfies the evidence standard for most Class II devices. Clinical data becomes necessary when technological differences raise questions bench testing alone cannot resolve.
The De Novo Pathway: Classification for Novel Devices
The De Novo pathway applies to novel devices with no legally marketed predicate. Without a predicate, a device defaults to Class III, which requires Premarket Approval (PMA). De Novo provides the FDA a mechanism to classify low-to-moderate-risk novel devices as Class I or Class II instead.
A successful De Novo request produces a De Novo Grant Order. That order:
- Authorizes the device for marketing
- Establishes a new classification regulation under 21 CFR
- Assigns a new FDA product code
- Defines applicable general and/or special controls
- Qualifies the device as a predicate for future 510(k) submissions from other manufacturers
The Two Submission Routes
| Route | When to Use |
|---|---|
| Direct De Novo | When no valid predicate exists and you choose to bypass the 510(k) pathway. |
| Post-NSE De Novo | When a 510(k) submission receives a Not Substantially Equivalent (NSE) determination and you pursue De Novo classification under 21 U.S.C. § 360c(f)(2). |
The Direct De Novo route avoids the cost and time of a predictable NSE outcome. Before either route, the FDA recommends a Pre-Submission (Q-Sub) consultation. Q-Sub meetings let manufacturers align with FDA reviewers on evidence expectations before full preparation begins.
510(k) vs. De Novo: A Direct Comparison
The 510(k) carries a lower cost and shorter review timeline when a valid predicate exists. The De Novo standard fee in FY2026 is more than six times higher. But De Novo produces a product classification that competitors must navigate, an advantage no 510(k) clearance creates.
| Factor | 510(k) | De Novo |
|---|---|---|
| Predicate Required | Yes | No |
| Eligible Classification | Class I or II | Class I or II (novel) |
| FDA Review Goal | 90 days | 150 days |
| FY2026 Standard User Fee | $26,067 | $173,782 |
| FY2026 Small Business Fee | $6,517 | $43,446 |
| Clinical Data | Not routinely required | Often required |
| Benefit-Risk Analysis | Not required | Required |
| Establishes New Classification | No | Yes |
| Creates New Predicate | No | Yes |
| Preparation Time | 3–6 months | 6–12 months |
Source: FDA.gov FY2026 MDUFA User Fees; FDA De Novo and 510(k) Guidance
How to Choose the Right Pathway
Predicate availability is your primary filter. Use this framework:
| Scenario | Recommended Pathway |
|---|---|
| Predicate exists with the same intended use and similar technology | 510(k) |
| Predicate exists, but technological differences raise new questions | 510(k) with additional performance data, or evaluate De Novo |
| No predicate exists; device is low to moderate risk | Direct De Novo |
| Prior 510(k) received an NSE determination | Post-NSE De Novo |
| No predicate exists; device is high risk | PMA |
When predicate availability is unclear, submit a 513(g) request before committing to a pathway. A 513(g) provides a formal FDA classification determination. The FY2026 standard fee is $7,820. That cost is minor compared to recovering from a misclassified submission.
Consider the long-term value of De Novo. A granted De Novo request establishes a new product classification. Future competitors entering the same device category must reference your device as their predicate. For AI-based diagnostic tools or novel connected health platforms without a prior predicate, that first-mover regulatory position is a durable competitive advantage, one a 510(k) clearance does not produce.
Navigate Medical Device Compliance with MiCOM Labs
MiCOM Labs provides A2LA-accredited compliance testing for medical device manufacturers supporting 510(k) and De Novo submissions. ISO/IEC 17025-compliant test reports meet FDA documentation and traceability standards for regulatory submissions.
Testing capabilities for medical device compliance include:
- EMC testing under IEC 60601-1-2
- IEC 60601-1 compliance evaluations for medical electrical equipment
- RF and wireless testing for US and international markets
- Antenna characterization and performance evaluation
Ready to Move from Pathway Selection to Testing?
Once you’ve identified the right pathway, your submission depends on test data the FDA will accept. MiCOM Labs delivers A2LA-accredited compliance testing under ISO/IEC 17025 for medical device manufacturers pursuing 510(k) and De Novo submissions, producing reports that meet FDA documentation and traceability standards.
Our automated MiTest® platform provides live project status and real-time data throughout testing, so your team stays informed and your timeline stays on track.
Contact MiCOM Labs to discuss your device specifications and testing requirements. Receive a detailed proposal outlining applicable standards, testing scope, and certification timelines.